MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.79
-0.48
-2.95%
After Hours: 15.79 0 0.00% 17:37 09/28 EDT
OPEN
16.09
PREV CLOSE
16.27
HIGH
16.24
LOW
15.76
VOLUME
515.56K
TURNOVER
--
52 WEEK HIGH
43.16
52 WEEK LOW
11.60
MARKET CAP
524.25M
P/E (TTM)
-3.0668
1D
5D
1M
3M
1Y
5Y
15 Best Short Squeeze Stocks To Buy Now
In this article, we discuss the 15 best short squeeze stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Short Squeeze Stocks To Buy Now. The retail investor frenzy at the stock market and the short sque...
Insider Monkey · 3d ago
Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive...
GlobeNewswire · 09/21 12:08
Intercept Pharmaceuticals to Repurchase $39.9 Million Convertible Notes
MT Newswires · 09/13 15:55
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ann...
GlobeNewswire · 09/13 12:00
Analysts Make the Case for Small-Cap Biotech Stocks This Fall (INMB, DVAX, SAVA, ICPT, IMGN, ATRX)
WallStreetPR · 09/09 11:07
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced th...
GlobeNewswire · 09/01 12:00
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
Benzinga · 08/23 09:06
Intercept Pharma Stock Falls as Goldman Cuts to Sell
Intercept Pharma shares traded lower after Goldman Sachs downgraded the stock to sell and lowered its price target to $10 from $17.
TheStreet.com · 08/20 14:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICPT. Analyze the recent business situations of Intercept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

10.53%Strong Buy
15.79%Buy
63.16%Hold
10.53%Under-perform
0.00%Sell
Analyst Price Target
The average ICPT stock price target is 31.63 with a high estimate of 82.00 and a low estimate of 10.00.
High82.00
Average31.63
Low10.00
Current 15.79
EPS
Actual
Estimate
-1.61-1.21-0.80-0.40
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 276
Institutional Holdings: 23.88M
% Owned: 71.93%
Shares Outstanding: 33.20M
TypeInstitutionsShares
Increased
53
2.00M
New
14
372.59K
Decreased
30
4.25M
Sold Out
35
655.22K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.50%
Pharmaceuticals & Medical Research
-1.90%
Key Executives
Non-Executive Chairman/Independent Director
Paolo Fundaro
President/Chief Executive Officer/Chief Operating Officer/Director
Jerome Durso
Chief Financial Officer
Andrew Saik
Corporate Executive
Lisa Bright
Chief Human Resource Officer
David Ford
Executive Vice President
Linda Richardson
Executive Vice President
Christian Weyer
Senior Vice President
Gail Cawkwell
Senior Vice President
Lisa DeFrancesco
Chief Accounting Officer/Controller
Rocco Venezia
Lead Director/Independent Director
Gino Santini
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Dagmar Rosa-bjorkeson
Independent Director
Glenn Sblendorio
No Data
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.